The LUX-Lung clinical trial programme is investigating afatinib* in a number of patient populations with advanced NSCLC. LUX-Lung 3 (n=364) and LUX-Lung 6 (n=345) represent the largest and most robust clinical registration programme in EGFR mutation-positive NSCLC to date. Read the infographic to find out more.
*In the EU, Taiwan and Mexico, afatinib is approved under the brand name GIOTRIF^®, and in the U.S. under the brand name GILOTRIF^® for use in patients with distinct types of NSCLC.